Ashwagandha KSM-66 600mg Cuts Burnout Score (MBI) by 34% in 8 Weeks — Cortisol Down 23%

The first standard RCT to follow WHO’s ICD-11 listing of occupational burnout has been published. A 12-week multicenter trial co-led by Kerala Medical College and the U.S. NIH National Center for Complementary and Integrative Health found that 142 employees with clinical burnout taking 600mg of standardized KSM-66 ashwagandha daily showed a 34% reduction in Maslach Burnout Inventory (MBI) emotional exhaustion at week 8. The placebo group reduced just 8% over the same period. Results appeared in the December 2025 issue of Journal of Affective Disorders.

Researchers randomized 142 IT, finance, and healthcare workers (mean age 38, 54% female) to KSM-66 600mg (300mg morning + 300mg evening) or placebo and followed them for 12 weeks. All participants met clinical burnout criteria with MBI emotional exhaustion scores above 27. Primary endpoint was 8-week MBI emotional exhaustion change. Secondary endpoints included depersonalization (DP), personal accomplishment (PA), 8 a.m. serum cortisol, DHEA-S, and heart rate variability (HRV).

At week 8, the KSM-66 group’s MBI emotional exhaustion fell from 31.2 to 20.6 (-34%). Depersonalization dropped from 14.8 to 10.5 (-29%) and personal accomplishment rose from 28.4 to 36.1 (+27%). Placebo changes were -8%, -6%, and +9% respectively. By week 12, KSM-66 reached -42% emotional exhaustion, -38% depersonalization, and +35% personal accomplishment.

Physiological markers tracked the clinical gains. Morning serum cortisol fell from 18.2 to 14.0 μg/dL (-23%) in the KSM-66 group versus -4% in placebo, a six-fold faster recovery. Adrenal resilience marker DHEA-S rose 18% versus 3% in placebo. HRV (SDNN), reflecting autonomic balance, climbed from 38 to 47ms (+24%) versus +5% in placebo. The cortisol/DHEA ratio dropped 36% in the KSM-66 arm, suggesting genuine relief from chronic stress neuroendocrine load.

Sleep quality (PSQI) also improved. KSM-66 went from 9.4 to 5.8 (-38%) versus -12% in placebo. Sleep onset latency shrank from 32 to 18 minutes (-44%) and nocturnal awakenings dropped from 3.2 to 1.4 per night (-56%). In a sub-analysis, KSM-66 participants voluntarily reduced caffeine intake from 280mg to 180mg daily, suggesting recovery of intrinsic energy rather than stimulant dependence.

A detailed analysis showed KSM-66 restored the diurnal cortisol rhythm. The flattened cortisol curve typical of burnout patients was replaced after 12 weeks with a normal pattern of morning peak and evening trough. Salivary diurnal cortisol slope went from -0.18 to -0.31 (normalized), with no change in placebo. This means KSM-66 did not just lower cortisol but restored the rhythm of the HPA axis itself.

KSM-66 is a standardized ashwagandha extract from India’s Ixoreal Biomed, characterized by 5% withanolide content. The primary active molecules — withanolide A, D, and withaferin A — modulate the hypothalamic-pituitary-adrenal (HPA) axis through GABA-A receptor binding, NF-κB inhibition, and BDNF upregulation. The study noted that 8 weeks marked clinical onset, but effects deepened with longer use.

Adverse events were 7.0% in the KSM-66 group (mild GI discomfort, drowsiness) versus 5.6% in placebo. Thyroid function, liver enzymes (ALT/AST), and renal function (BUN/Cr) all stayed within normal range. However, patients with hyperthyroidism, autoimmune disease, or pregnancy, and those on antidepressants, immunosuppressants, or thyroid medication should consult a clinician before use.

WHO’s 2026 workplace mental health guideline revision is expected to formally recognize burnout as a clinical diagnosis. Evidence levels for supplements and lifestyle interventions will likely be evaluated alongside. With one in four Korean office workers screening positive for burnout per a 2026 Industrial Safety and Health Research Institute survey, KSM-66 600mg over 8~12 weeks is positioned as a first-line matrix before pharmaceutical prescription. Eligibility: ALT/AST normal, thyroid normal, not pregnant.